title: Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator.
abstract: Liver X receptors (LXRs) are ligand-activated transcription factors that belong to the nuclear receptor superfamily. LXRs activate transcription of a spectrum of genes that regulate reverse cholesterol transport, including the ATP binding cassette transporter A1 (ABCA1), and raise HDL cholesterol (HDL-C) levels. However, LXR agonists also induce genes that stimulate lipogenesis, including the sterol response element binding protein (SREBP1-c) and fatty acid synthetase (FAS). The induction of these genes in the liver cause increased hepatic triglyceride synthesis, hypertriglyceridemia, and hepatic steatosis. As LXR response elements have been identified in these promoters, it is not clear if these two processes can be separated. Herein, we demonstrate that plasma HDL-C elevation and intestinal ABCA1 induction can occur with relatively little induction of FAS and SREBP1-c in mouse liver via a selective LXR modulator GW3965. This is in contrast to the strong induction of hepatic lipogenic genes by the well-characterized LXR agonist T0901317 (T317). Consistent with the in vivo results, GW3965 is a very weak LXR activator compared with T317 in human hepatoma cells. GW3965-liganded LXR recruits selected coactivators less effectively than T317 and may explain in part the tissue selective gene induction. This demonstration that tissue and gene selective modulation is possible with selective LXR modulators has positive implications for the development of this class of antiatherosclerotic agents.
authors.affiliation: Cardiovascular Biology, Bristol-Myers Squibb Company, Experimental Station, Wilmington, DE 19880, USA.
authors.forename: Bowman
authors.initials: B
authors.lastname: Miao
authors.forename: Susan
authors.initials: S
authors.lastname: Zondlo
authors.forename: Sandy
authors.initials: S
authors.lastname: Gibbs
authors.forename: Debra
authors.initials: D
authors.lastname: Cromley
authors.forename: Vinayak P
authors.initials: VP
authors.lastname: Hosagrahara
authors.forename: Todd G
authors.initials: TG
authors.lastname: Kirchgessner
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Billheimer
authors.forename: Ranjan
authors.initials: R
authors.lastname: Mukherjee
mesh_terms: D000818:Animals; D001565:Benzoates / Q000494:pharmacology*; D001596:Benzylamines / Q000494:pharmacology*; D008076:Cholesterol, HDL / Q000097:blood*; D004268:DNA-Binding Proteins; D005234:Fatty Liver / Q000378:metabolism*; D015228:Hypertriglyceridemia / Q000378:metabolism*; D008024:Ligands; D000071518:Liver X Receptors; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009928:Organ Specificity; D057093:Orphan Nuclear Receptors; D018160:Receptors, Cytoplasmic and Nuclear / Q000187:drug effects*
chemical_list: D001565:Benzoates; D001596:Benzylamines; D008076:Cholesterol, HDL; D004268:DNA-Binding Proteins; C473027:GW 3965; D008024:Ligands; D000071518:Liver X Receptors; D057093:Orphan Nuclear Receptors; D018160:Receptors, Cytoplasmic and Nuclear